While curing major diseases like cancer and heart disease might extend life expectancy by only a few years, a combined cure would still only raise it to about 90 years.

Public health advancements have significantly extended life, but many individuals over 60 are experiencing what is termed 'manufactured time' due to these medical interventions.

Recent studies indicate that the rapid increases in life expectancy seen in the 20th century have come to a halt, particularly among long-lived populations.

Insights from 'vanguard groups' of longer-lived individuals can inform factors influencing longevity, though these findings may not apply universally.

While healthier lifestyles can improve individual health outcomes, their impact on national life expectancy is limited compared to medical interventions.

An analysis from over 30 years ago indicated that achieving a life expectancy of 100 years would necessitate unrealistic reductions in death rates.

The question of human lifespan has significant implications for science and public policy, especially as more individuals live longer.

Investing in aging research could yield significant economic benefits, underscoring the importance of prioritizing interventions that address the biological aspects of aging.

Historical data suggests that life expectancy is likely to plateau around 85 years once a significant majority of people survive past age 65.

A primary limitation to increasing lifespan is the biological aging process, which becomes increasingly apparent as longevity rises.

Geroscience research suggests that the aging process is modifiable, presenting opportunities to enhance both healthspan and longevity.

The concept of 'expansion of morbidity' indicates that as life expectancy increases, so does the prevalence of chronic diseases, highlighting the need to focus on aging itself rather than just diseases.